海沧区厦门生物医药港，30年前还是一片甘蔗地。如今，在这片规划面积6.58平方公里的土地上，上演着中国生物医药产业的创新奇迹：培育出特宝生物等细分领域龙头企业，书写了一部从"政 近日，上海证券报记者走进特宝生物，听其创始人、董事长孙黎讲述特宝生物向未来开放，在创新中不迷失的故事。 解决"人有我无"问题 成立于1996年的特宝生物，主要从事重组蛋白质及其长效修饰药物研发、生产及销售，以免疫相关细胞因子药物研发为核心，致力于为肝病、肿瘤、代谢性相关疾病等治疗领域提供更优解决方 "早期工作解决的是'西方有，我们没有'的问题。20世纪90年代中期，进口药品价格极高。当时一克黄金才100元左右，而一支国外进口的可用于化疗和放疗过程中升白辅助治疗的特尔立同类药 三十载耕耘守初心。目前，特宝生物已构建起以聚乙二醇长效化药物为核心的创新平台技术，已上市包括派格宾、益佩生、珮金等多款聚乙二醇长效化国家1类新药。 数据显示，2018至2024年，特宝生物经营业绩每年均保持增长，营业收入从4.48亿元增加至28.17亿元，净利润从1600万元增加至8.27亿元。 研发过程"九死一生" 特宝生物的成长史，是厦门改革开放实践的一个缩影 ...

Core Insights - The article highlights that only 13 women globally have become billionaires by founding healthcare companies, with 7 of them from China, indicating a significant presence of Chinese female entrepreneurs in the healthcare sector [1][3]. Industry Overview - The Chinese biopharmaceutical industry is experiencing a transformative phase, referred to as the "DeepSeek moment," as it evolves from being a "generic drug powerhouse" to a competitive force against Western innovation in pharmaceuticals [2]. - In 2024, over 1,250 new drug candidates are expected to enter the research and development phase in China, surpassing the European Union and nearly matching the United States' 1,440 candidates [2]. - Nearly one-third of the drug candidates licensed by large pharmaceutical companies in 2024 are from Chinese firms, a significant increase from zero in 2019 [3]. Company Highlights - **Hansoh Pharmaceutical Group**: Founded by Zhong Huijuan, the company reported a total revenue of approximately 12.26 billion yuan in 2024, with a year-on-year growth of about 21.3% [7]. - **Aimeike**: Founded by Jian Jun, the company specializes in hyaluronic acid production and was listed on the A-share market in 2020, achieving a market value exceeding 170 billion yuan [10]. - **Qizheng Tibetan Medicine**: Founded by Lei Jufang, the company generated sales revenue of 1.655 billion yuan in 2024, with a year-on-year growth of 16.31% [14]. - **Haisco Pharmaceutical Group**: Co-founded by Fan Xiulian, the company reported a revenue of 3.721 billion yuan in 2024, with a year-on-year increase of 10.92% [17]. - **Teva Biopharmaceuticals**: Founded by Yang Ying, the company has shown rapid growth, with revenues increasing from 1.527 billion yuan in 2022 to 2.817 billion yuan in 2024 [18]. - **Kangfang Biopharmaceutical**: Founded by Xia Yu, the company has developed several innovative drugs and is recognized for its leading position in the biopharmaceutical sector [23]. - **Xinlitai**: Co-founded by Liao Qingqing, the company has shifted focus to self-research and development, achieving a revenue of 4.012 billion yuan in 2024, with a year-on-year growth of 19.22% [26].

Core Viewpoint - Teabo Bio's performance continues to grow significantly in the hepatitis B field, with a strong increase in revenue and net profit in Q1 2025 compared to the previous year [1][2]. Financial Performance - In Q1 2025, Teabo Bio achieved revenue of 673 million yuan, a year-on-year increase of 23.48%, and a net profit of 182 million yuan, up 41.4% [1]. - From 2020 to 2024, the company's revenue grew from 794 million yuan to 2.817 billion yuan, while net profit increased from 117 million yuan to 828 million yuan [2]. - The company has maintained a continuous dual increase in revenue and net profit for seven consecutive years, with a cumulative net profit of 1.968 billion yuan since its IPO [2]. Product Development - The growth in performance is attributed to the stable sales of the key product, Peginterferon, which is a first-in-class drug with complete independent intellectual property rights [2]. - Teabo Bio has invested significantly in R&D, with expenditures rising from 76.68 million yuan in 2020 to 295 million yuan in 2024, totaling 833 million yuan over the five years [2]. Intellectual Property and Market Position - As of the end of 2024, Teabo Bio has obtained 16 invention patents and a total of 293 intellectual property rights [3]. - The company has made important progress in multiple R&D projects, including the acceptance of a drug registration application for its self-developed growth hormone injection in January 2024 [3]. Stock Performance - Teabo Bio's stock price has seen a significant increase, rising from an IPO price of 8.24 yuan per share to 78.96 yuan per share as of April 22, representing a cumulative increase of 858.25% [3].